Report Detail
Global Overactive Bladder (OAB) Therapeutics Market Research Report 2019
- RnM3116696 |
- 13 March, 2019 |
- Global |
- 100 Pages |
- QYResearch |
- Pharma & Healthcare
Overactive bladder is a medical syndrome, defined by urinary incontinence usually characterized by high urine frequency or nocturia. The common symptoms of OAB includes urgency, high urinary frequency and urge incontinence. Anticholinergic agents are considered as the first line treatment for overactive bladder disorders. Flavoxate, oxybutynin, tolterodine are some of the generic drugs used for the treatment of overactive bladder. These drugs acts by antagonizing cholinergic receptors that provides the relief from the frequent urination.
Increasing population diagnosed with overactive bladder disorder coupled with aging population will drive the growth of this market. Furthermore, manufacturers are continuously increasing their research and development expenditure to develop novel drugs such as neuromuscular blocking agents with innovative mechanism of actions. This factor will provide healthy platform to develop this market and hence drives the market growth.
The global Overactive Bladder (OAB) Therapeutics market is valued at xx million US$ in 2018 is expected to reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025.
This report focuses on Overactive Bladder (OAB) Therapeutics volume and value at global level, regional level and company level. From a global perspective, this report represents overall Overactive Bladder (OAB) Therapeutics market size by analyzing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan.
At company level, this report focuses on the production capacity, ex-factory price, revenue and market share for each manufacturer covered in this report.
The following manufacturers are covered:
Allergan
Astellas Pharma
Hisamitsu Pharmaceutical
Pfizer
Ferring
GlaxoSmithKline
Ion Channel Innovations
Kwang Dong Pharmaceutical
Lanzhou Institute of Biological Products
Merck
ONO Pharmaceutical
Sanofi
Tengion
Teva Pharmaceutical Industries
Segment by Regions
North America
Europe
China
Japan
Segment by Type
Anticholinergic Agents
Beta-3 Adrenoreceptor Agonists
Segment by Application
Hosptial
Clinci
Other
Table of Contents
Executive Summary
1 Overactive Bladder (OAB) Therapeutics Market Overview
- 1.1 Product Overview and Scope of Overactive Bladder (OAB) Therapeutics
- 1.2 Overactive Bladder (OAB) Therapeutics Segment by Type
- 1.2.1 Global Overactive Bladder (OAB) Therapeutics Production Growth Rate Comparison by Type (2014-2025)
- 1.2.2 Anticholinergic Agents
- 1.2.3 Beta-3 Adrenoreceptor Agonists
- 1.3 Overactive Bladder (OAB) Therapeutics Segment by Application
- 1.3.1 Overactive Bladder (OAB) Therapeutics Consumption Comparison by Application (2014-2025)
- 1.3.2 Hosptial
- 1.3.3 Clinci
- 1.3.4 Other
- 1.4 Global Overactive Bladder (OAB) Therapeutics Market by Region
- 1.4.1 Global Overactive Bladder (OAB) Therapeutics Market Size Region
- 1.4.2 North America Status and Prospect (2014-2025)
- 1.4.3 Europe Status and Prospect (2014-2025)
- 1.4.4 China Status and Prospect (2014-2025)
- 1.4.5 Japan Status and Prospect (2014-2025)
- 1.5 Global Overactive Bladder (OAB) Therapeutics Market Size
- 1.5.1 Global Overactive Bladder (OAB) Therapeutics Revenue (2014-2025)
- 1.5.2 Global Overactive Bladder (OAB) Therapeutics Production (2014-2025)
2 Global Overactive Bladder (OAB) Therapeutics Market Competition by Manufacturers
- 2.1 Global Overactive Bladder (OAB) Therapeutics Production Market Share by Manufacturers (2014-2019)
- 2.2 Global Overactive Bladder (OAB) Therapeutics Revenue Share by Manufacturers (2014-2019)
- 2.3 Global Overactive Bladder (OAB) Therapeutics Average Price by Manufacturers (2014-2019)
- 2.4 Manufacturers Overactive Bladder (OAB) Therapeutics Production Sites, Area Served, Product Types
- 2.5 Overactive Bladder (OAB) Therapeutics Market Competitive Situation and Trends
- 2.5.1 Overactive Bladder (OAB) Therapeutics Market Concentration Rate
- 2.5.2 Overactive Bladder (OAB) Therapeutics Market Share of Top 3 and Top 5 Manufacturers
- 2.5.3 Mergers & Acquisitions, Expansion
3 Global Overactive Bladder (OAB) Therapeutics Production Market Share by Regions
- 3.1 Global Overactive Bladder (OAB) Therapeutics Production Market Share by Regions
- 3.2 Global Overactive Bladder (OAB) Therapeutics Revenue Market Share by Regions (2014-2019)
- 3.3 Global Overactive Bladder (OAB) Therapeutics Production, Revenue, Price and Gross Margin (2014-2019)
- 3.4 North America Overactive Bladder (OAB) Therapeutics Production
- 3.4.1 North America Overactive Bladder (OAB) Therapeutics Production Growth Rate (2014-2019)
- 3.4.2 North America Overactive Bladder (OAB) Therapeutics Production, Revenue, Price and Gross Margin (2014-2019)
- 3.5 Europe Overactive Bladder (OAB) Therapeutics Production
- 3.5.1 Europe Overactive Bladder (OAB) Therapeutics Production Growth Rate (2014-2019)
- 3.5.2 Europe Overactive Bladder (OAB) Therapeutics Production, Revenue, Price and Gross Margin (2014-2019)
- 3.6 China Overactive Bladder (OAB) Therapeutics Production (2014-2019)
- 3.6.1 China Overactive Bladder (OAB) Therapeutics Production Growth Rate (2014-2019)
- 3.6.2 China Overactive Bladder (OAB) Therapeutics Production, Revenue, Price and Gross Margin (2014-2019)
- 3.7 Japan Overactive Bladder (OAB) Therapeutics Production (2014-2019)
- 3.7.1 Japan Overactive Bladder (OAB) Therapeutics Production Growth Rate (2014-2019)
- 3.7.2 Japan Overactive Bladder (OAB) Therapeutics Production, Revenue, Price and Gross Margin (2014-2019)
4 Global Overactive Bladder (OAB) Therapeutics Consumption by Regions
- 4.1 Global Overactive Bladder (OAB) Therapeutics Consumption by Regions
- 4.2 North America Overactive Bladder (OAB) Therapeutics Consumption (2014-2019)
- 4.3 Europe Overactive Bladder (OAB) Therapeutics Consumption (2014-2019)
- 4.4 China Overactive Bladder (OAB) Therapeutics Consumption (2014-2019)
- 4.5 Japan Overactive Bladder (OAB) Therapeutics Consumption (2014-2019)
5 Global Overactive Bladder (OAB) Therapeutics Production, Revenue, Price Trend by Type
- 5.1 Global Overactive Bladder (OAB) Therapeutics Production Market Share by Type (2014-2019)
- 5.2 Global Overactive Bladder (OAB) Therapeutics Revenue Market Share by Type (2014-2019)
- 5.3 Global Overactive Bladder (OAB) Therapeutics Price by Type (2014-2019)
- 5.4 Global Overactive Bladder (OAB) Therapeutics Production Growth by Type (2014-2019)
6 Global Overactive Bladder (OAB) Therapeutics Market Analysis by Applications
- 6.1 Global Overactive Bladder (OAB) Therapeutics Consumption Market Share by Application (2014-2019)
- 6.2 Global Overactive Bladder (OAB) Therapeutics Consumption Growth Rate by Application (2014-2019)
7 Company Profiles and Key Figures in Overactive Bladder (OAB) Therapeutics Business
- 7.1 Allergan
- 7.1.1 Allergan Overactive Bladder (OAB) Therapeutics Production Sites and Area Served
- 7.1.2 Overactive Bladder (OAB) Therapeutics Product Introduction, Application and Specification
- 7.1.3 Allergan Overactive Bladder (OAB) Therapeutics Production, Revenue, Price and Gross Margin (2014-2019)
- 7.1.4 Main Business and Markets Served
- 7.2 Astellas Pharma
- 7.2.1 Astellas Pharma Overactive Bladder (OAB) Therapeutics Production Sites and Area Served
- 7.2.2 Overactive Bladder (OAB) Therapeutics Product Introduction, Application and Specification
- 7.2.3 Astellas Pharma Overactive Bladder (OAB) Therapeutics Production, Revenue, Price and Gross Margin (2014-2019)
- 7.2.4 Main Business and Markets Served
- 7.3 Hisamitsu Pharmaceutical
- 7.3.1 Hisamitsu Pharmaceutical Overactive Bladder (OAB) Therapeutics Production Sites and Area Served
- 7.3.2 Overactive Bladder (OAB) Therapeutics Product Introduction, Application and Specification
- 7.3.3 Hisamitsu Pharmaceutical Overactive Bladder (OAB) Therapeutics Production, Revenue, Price and Gross Margin (2014-2019)
- 7.3.4 Main Business and Markets Served
- 7.4 Pfizer
- 7.4.1 Pfizer Overactive Bladder (OAB) Therapeutics Production Sites and Area Served
- 7.4.2 Overactive Bladder (OAB) Therapeutics Product Introduction, Application and Specification
- 7.4.3 Pfizer Overactive Bladder (OAB) Therapeutics Production, Revenue, Price and Gross Margin (2014-2019)
- 7.4.4 Main Business and Markets Served
- 7.5 Ferring
- 7.5.1 Ferring Overactive Bladder (OAB) Therapeutics Production Sites and Area Served
- 7.5.2 Overactive Bladder (OAB) Therapeutics Product Introduction, Application and Specification
- 7.5.3 Ferring Overactive Bladder (OAB) Therapeutics Production, Revenue, Price and Gross Margin (2014-2019)
- 7.5.4 Main Business and Markets Served
- 7.6 GlaxoSmithKline
- 7.6.1 GlaxoSmithKline Overactive Bladder (OAB) Therapeutics Production Sites and Area Served
- 7.6.2 Overactive Bladder (OAB) Therapeutics Product Introduction, Application and Specification
- 7.6.3 GlaxoSmithKline Overactive Bladder (OAB) Therapeutics Production, Revenue, Price and Gross Margin (2014-2019)
- 7.6.4 Main Business and Markets Served
- 7.7 Ion Channel Innovations
- 7.7.1 Ion Channel Innovations Overactive Bladder (OAB) Therapeutics Production Sites and Area Served
- 7.7.2 Overactive Bladder (OAB) Therapeutics Product Introduction, Application and Specification
- 7.7.3 Ion Channel Innovations Overactive Bladder (OAB) Therapeutics Production, Revenue, Price and Gross Margin (2014-2019)
- 7.7.4 Main Business and Markets Served
- 7.8 Kwang Dong Pharmaceutical
- 7.8.1 Kwang Dong Pharmaceutical Overactive Bladder (OAB) Therapeutics Production Sites and Area Served
- 7.8.2 Overactive Bladder (OAB) Therapeutics Product Introduction, Application and Specification
- 7.8.3 Kwang Dong Pharmaceutical Overactive Bladder (OAB) Therapeutics Production, Revenue, Price and Gross Margin (2014-2019)
- 7.8.4 Main Business and Markets Served
- 7.9 Lanzhou Institute of Biological Products
- 7.9.1 Lanzhou Institute of Biological Products Overactive Bladder (OAB) Therapeutics Production Sites and Area Served
- 7.9.2 Overactive Bladder (OAB) Therapeutics Product Introduction, Application and Specification
- 7.9.3 Lanzhou Institute of Biological Products Overactive Bladder (OAB) Therapeutics Production, Revenue, Price and Gross Margin (2014-2019)
- 7.9.4 Main Business and Markets Served
- 7.10 Merck
- 7.10.1 Merck Overactive Bladder (OAB) Therapeutics Production Sites and Area Served
- 7.10.2 Overactive Bladder (OAB) Therapeutics Product Introduction, Application and Specification
- 7.10.3 Merck Overactive Bladder (OAB) Therapeutics Production, Revenue, Price and Gross Margin (2014-2019)
- 7.10.4 Main Business and Markets Served
- 7.11 ONO Pharmaceutical
- 7.12 Sanofi
- 7.13 Tengion
- 7.14 Teva Pharmaceutical Industries
8 Overactive Bladder (OAB) Therapeutics Manufacturing Cost Analysis
- 8.1 Overactive Bladder (OAB) Therapeutics Key Raw Materials Analysis
- 8.1.1 Key Raw Materials
- 8.1.2 Price Trend of Key Raw Materials
- 8.1.3 Key Suppliers of Raw Materials
- 8.2 Proportion of Manufacturing Cost Structure
- 8.3 Manufacturing Process Analysis of Overactive Bladder (OAB) Therapeutics
- 8.4 Overactive Bladder (OAB) Therapeutics Industrial Chain Analysis
9 Marketing Channel, Distributors and Customers
- 9.1 Marketing Channel
- 9.1.1 Direct Marketing
- 9.1.2 Indirect Marketing
- 9.2 Overactive Bladder (OAB) Therapeutics Distributors List
- 9.3 Overactive Bladder (OAB) Therapeutics Customers
10 Market Dynamics
- 10.1 Market Trends
- 10.2 Opportunities
- 10.3 Market Drivers
- 10.4 Challenges
- 10.5 Influence Factors
11 Global Overactive Bladder (OAB) Therapeutics Market Forecast
- 11.1 Global Overactive Bladder (OAB) Therapeutics Production, Revenue Forecast
- 11.1.1 Global Overactive Bladder (OAB) Therapeutics Production Growth Rate Forecast (2019-2025)
- 11.1.2 Global Overactive Bladder (OAB) Therapeutics Revenue and Growth Rate Forecast (2019-2025)
- 11.1.3 Global Overactive Bladder (OAB) Therapeutics Price and Trend Forecast (2019-2025)
- 11.2 Global Overactive Bladder (OAB) Therapeutics Production Forecast by Regions (2019-2025)
- 11.2.1 North America Overactive Bladder (OAB) Therapeutics Production, Revenue Forecast (2019-2025)
- 11.2.2 Europe Overactive Bladder (OAB) Therapeutics Production, Revenue Forecast (2019-2025)
- 11.2.3 China Overactive Bladder (OAB) Therapeutics Production, Revenue Forecast (2019-2025)
- 11.2.4 Japan Overactive Bladder (OAB) Therapeutics Production, Revenue Forecast (2019-2025)
- 11.3 Global Overactive Bladder (OAB) Therapeutics Consumption Forecast by Regions (2019-2025)
- 11.3.1 North America Overactive Bladder (OAB) Therapeutics Consumption Forecast (2019-2025)
- 11.3.2 Europe Overactive Bladder (OAB) Therapeutics Consumption Forecast (2019-2025)
- 11.3.3 China Overactive Bladder (OAB) Therapeutics Consumption Forecast (2019-2025)
- 11.3.4 Japan Overactive Bladder (OAB) Therapeutics Consumption Forecast (2019-2025)
- 11.4 Global Overactive Bladder (OAB) Therapeutics Production, Revenue and Price Forecast by Type (2019-2025)
- 11.5 Global Overactive Bladder (OAB) Therapeutics Consumption Forecast by Application (2019-2025)
12 Research Findings and Conclusion
13 Methodology and Data Source
- 13.1 Methodology/Research Approach
- 13.1.1 Research Programs/Design
- 13.1.2 Market Size Estimation
- 13.1.3 Market Breakdown and Data Triangulation
- 13.2 Data Source
- 13.2.1 Secondary Sources
- 13.2.2 Primary Sources
- 13.3 Author List
Summary:
Get latest Market Research Reports on Overactive Bladder (OAB) Therapeutics . Industry analysis & Market Report on Overactive Bladder (OAB) Therapeutics is a syndicated market report, published as Global Overactive Bladder (OAB) Therapeutics Market Research Report 2019. It is complete Research Study and Industry Analysis of Overactive Bladder (OAB) Therapeutics market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
